

# InÃ¡s BÃ¡rtolo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3364223/publications.pdf>

Version: 2024-02-01

29  
papers

604  
citations

687363

13  
h-index

642732

23  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1117  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance. <i>Nature Microbiology</i> , 2020, 5, 443-454.	13.3	114
2	Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: New insights into the origins of the AIDS pandemic. <i>Infection, Genetics and Evolution</i> , 2009, 9, 672-682.	2.3	44
3	Baseline susceptibility of primary HIV-2 to entry inhibitors. <i>Antiviral Therapy</i> , 2012, 17, 565-570.	1.0	44
4	Evaluation of the Clinical Sensitivities of Three Viral Load Assays with Plasma Samples from a Pediatric Population Predominantly Infected with Human Immunodeficiency Virus Type 1 Subtype G and BG Recombinant Forms. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3361-3367.	3.9	37
5	Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 34942-34953.	8.0	32
6	Origin and Epidemiological History of HIV-1 CRF14_BG. <i>PLoS ONE</i> , 2011, 6, e24130.	2.5	28
7	Evolutionary and Structural Features of the C2, V3 and C3 Envelope Regions Underlying the Differences in HIV-1 and HIV-2 Biology and Infection. <i>PLoS ONE</i> , 2011, 6, e14548.	2.5	27
8	HIV-1 Genetic Diversity and Transmitted Drug Resistance in Health Care Settings in Maputo, Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 323-331.	2.1	25
9	High Genetic Diversity of Human Immunodeficiency Virus Type 1 in Angola. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 306-310.	1.1	22
10	Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Healthcare Settings in Mozambique. <i>PLoS ONE</i> , 2013, 8, e82718.	2.5	21
11	Antiretroviral Drug Resistance Surveillance among Treatment-Naive Human Immunodeficiency Virus Type 1-Infected Individuals in Angola: Evidence for Low Level of Transmitted Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3156-3158.	3.2	20
12	Synthesis and structure-activity relationships of new chiral spiro- $\beta$ -lactams highly active against HIV-1 and Plasmodium. <i>European Journal of Medicinal Chemistry</i> , 2021, 219, 113439.	5.5	19
13	HIV-1 Diversity, Transmission Dynamics and Primary Drug Resistance in Angola. <i>PLoS ONE</i> , 2014, 9, e113626.	2.5	17
14	Pyromellitic dianhydride crosslinked soluble cyclodextrin polymers: Synthesis, lopinavir release from sub-micron sized particles and anti-HIV-1 activity. <i>International Journal of Pharmaceutics</i> , 2020, 583, 119356.	5.2	17
15	Spiro-Lactams as Novel Antimicrobial Agents. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 140-152.	2.1	16
16	Seronegative infection and AIDS caused by an A2 subtype HIV-1. <i>Aids</i> , 2004, 18, 1071-1074.	2.2	13
17	Rapid clinical progression to AIDS and death in a persistently seronegative HIV-1 infected heterosexual young man. <i>Aids</i> , 2009, 23, 2359-2362.	2.2	12
18	Donor-Recipient Identification in Para- and Poly-phyletic Trees Under Alternative HIV-1 Transmission Hypotheses Using Approximate Bayesian Computation. <i>Genetics</i> , 2017, 207, 1089-1101.	2.9	12

#	ARTICLE	IF	CITATIONS
19	Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response. <i>Retrovirology</i> , 2013, 10, 110.	2.0	11
20	Rare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in Angola. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 822-828.	1.1	11
21	On the contribution of Angola to the initial spread of HIV-1. <i>Infection, Genetics and Evolution</i> , 2016, 46, 219-222.	2.3	11
22	Spiro-Î²-lactam BSS-730A Displays Potent Activity against HIV and Plasmodium. <i>ACS Infectious Diseases</i> , 2021, 7, 421-434.	3.8	11
23	Evaluation of the diagnostic performance of the rapid test VIKIA HIV1/2 in a highly complex HIV-1 epidemic. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 90-92.	1.8	7
24	Genetic Diversity and Drug Resistance Profiles in HIV Type 1- and HIV Type 2-Infected Patients from Cape Verde Islands. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 510-522.	1.1	6
25	Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. <i>PLoS ONE</i> , 2018, 13, e0195744.	2.5	6
26	Accidental Father-to-Son HIV-1 Transmission During the Seroconversion Period. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 857-862.	1.1	6
27	A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. <i>Vaccines</i> , 2020, 8, 171.	4.4	6
28	InÂvitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2. <i>Antiviral Research</i> , 2019, 161, 85-89.	4.1	3
29	Anti-HIV-1 Activity of pepRF1, a Proteolysis-Resistant CXCR4 Antagonist Derived from Dengue Virus Capsid Protein. <i>ACS Infectious Diseases</i> , 2021, 7, 6-22.	3.8	3